Samsung Medical Center: Adenocarcinoma trials

The registry lists 20 Adenocarcinoma studies with Samsung Medical Center as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 14Phase 3 2Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic AdenocarcinomaNot yet recruitingNCT06015321Phase 2
• Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic AnalysisCompletedNCT02589496Phase 2Results posted
• The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer SurgeryCompletedNCT05872334Not applicable
• As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to BiomarkersStatus unknownNCT04656002Phase 2
• Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.Status unknownNCT04258072Phase 1
• Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cmStatus unknownNCT03254004Phase 2
• Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO OverexpressionCompletedNCT03052478Phase 2
• Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic AnalysisCompletedNCT02628951Phase 2
• Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line ChemotherapyTerminatedNCT02449655Phase 2
• Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line ChemotherapyCompletedNCT02448329Phase 2
• Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line ChemotherapyCompletedNCT02448290Phase 2
• Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line TreatmentCompletedNCT02447406Phase 1/2
• Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line TreatmentCompletedNCT02447380Phase 2
• A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line ChemotherapyCompletedNCT02435108Phase 2
• Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT02426281Phase 2
• Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract AdenocarcinomaCompletedNCT02346032Phase 2
• Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment StrategyStatus unknownNCT01482585
• Clinical Outcomes of Endoscopic Resection for Treating WHYX LesionCompletedNCT01451034Phase 4
• Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyStatus unknownNCT01066195Phase 3
• Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric AdenocarcinomaCompletedNCT00323830Phase 3